How Do You Spell CILASTATIN?

1. Cilastatin is a pharmaceutical drug that belongs to the class of medicines known as renal dehydropeptidase inhibitors. It is primarily used in combination with the antibiotic drug imipenem to enhance its effectiveness. Cilastatin works by inhibiting the enzyme dehydropeptidase, which is responsible for breaking down imipenem in the kidneys. By inhibiting this enzyme, cilastatin helps to prevent the rapid breakdown of imipenem, thereby increasing its concentration and efficacy in the body.

   Imipenem and cilastatin therapy is commonly employed in the treatment of severe bacterial infections, particularly those caused by multi-drug resistant strains. This combination medication is effective against a wide range of bacteria, including both gram-positive and gram-negative organisms.

   As a renal dehydropeptidase inhibitor, cilastatin is mainly used in patients with renal impairment, as individuals with compromised kidney function may have lower levels of dehydropeptidase activity. By administering cilastatin alongside imipenem, it ensures sufficient drug concentration is maintained in the body, even in patients with reduced renal function.

   Cilastatin is typically administered intravenously, and its dosage may vary depending on factors such as the patient's age, weight, and the severity of the infection being treated. Like any medication, cilastatin may have potential side effects, which can include diarrhea, nausea, vomiting, allergic reactions, and changes in kidney function.

   This drug is available only by prescription, and its use should be supervised by a healthcare professional to ensure safe and appropriate usage.

Common Misspellings for CILASTATIN

The word "Cilastatin" is derived from the components "cila-" and "-statin".

The prefix "cila-" is derived from the drug's generic name cefazolin. "Cila-" refers to the compound's cephalosporin structure.

The suffix "-statin" is a common suffix used in pharmacology to indicate the drug's specific mechanism of action. In this case, "Cilastatin" indicates that the drug is a competitive inhibitor of the enzyme dehydropeptidase I (DHP-I), which acts to metabolize the antibiotic cefazolin in the kidneys.